7-octadecynoic acid is a lipid of Fatty Acyls (FA) class.
We collected disease MeSH terms mapped to the references associated with 7-octadecynoic acid
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Ha H et al. | Lipid rafts are important for the association of RANK and TRAF6. | 2003 | Exp. Mol. Med. | pmid:14508068 |
Brändström H et al. | Single nucleotide polymorphisms in the human gene for osteoprotegerin are not related to bone mineral density or fracture in elderly women. | 2004 | Calcif. Tissue Int. | pmid:14508625 |
Seidlova-Wuttke D et al. | Evidence for selective estrogen receptor modulator activity in a black cohosh (Cimicifuga racemosa) extract: comparison with estradiol-17beta. | 2003 | Eur. J. Endocrinol. | pmid:14514351 |
Sattler AM et al. | Novel aspects on RANK ligand and osteoprotegerin in osteoporosis and vascular disease. | 2004 | Calcif. Tissue Int. | pmid:14523602 |
Bergh JJ et al. | Osteoprotegerin expression and secretion are regulated by calcium influx through the L-type voltage-sensitive calcium channel. | 2004 | Endocrinology | pmid:14525906 |
Malyszko J et al. | Osteoprotegerin and its correlations with new markers of bone formation and bone resorption in kidney transplant recipients. | 2003 | Transplant. Proc. | pmid:14529897 |
Ren W et al. | Distinct gene expression of receptor activator of nuclear factor-kappaB and rank ligand in the inflammatory response to variant morphologies of UHMWPE particles. | 2003 | Biomaterials | pmid:14530078 |
Wiethe C et al. | Enhanced effector and memory CTL responses generated by incorporation of receptor activator of NF-kappa B (RANK)/RANK ligand costimulatory molecules into dendritic cell immunogens expressing a human tumor-specific antigen. | 2003 | J. Immunol. | pmid:14530334 |
Wagner EF and Matsuo K | Signalling in osteoclasts and the role of Fos/AP1 proteins. | 2003 | Ann. Rheum. Dis. | pmid:14532157 |
Ueland T et al. | Growth hormone substitution increases gene expression of members of the IGF family in cortical bone from women with adult onset growth hormone deficiency--relationship with bone turn-over. | 2003 | Bone | pmid:14555269 |
Nagata N et al. | Inhibition of RANKL-induced osteoclast formation in mouse bone marrow cells by IL-12: involvement of IFN-gamma possibly induced from non-T cell population. | 2003 | Bone | pmid:14555278 |
Smith BB et al. | A toxicity profile of osteoprotegerin in the cynomolgus monkey. | 2003 Sep-Oct | Int. J. Toxicol. | pmid:14555415 |
Cho TJ et al. | Tumor necrosis factor alpha activation of the apoptotic cascade in murine articular chondrocytes is associated with the induction of metalloproteinases and specific pro-resorptive factors. | 2003 | Arthritis Rheum. | pmid:14558090 |
von Tirpitz C et al. | Effect of systemic glucocorticoid therapy on bone metabolism and the osteoprotegerin system in patients with active Crohn's disease. | 2003 | Eur J Gastroenterol Hepatol | pmid:14560148 |
Fan X et al. | Nitric oxide regulates receptor activator of nuclear factor-kappaB ligand and osteoprotegerin expression in bone marrow stromal cells. | 2004 | Endocrinology | pmid:14563699 |
Barillé-Nion S and Bataille R | New insights in myeloma-induced osteolysis. | 2003 | Leuk. Lymphoma | pmid:14565645 |
Novack DV | TSH, the bone suppressing hormone. | 2003 | Cell | pmid:14567908 |
Abe E et al. | TSH is a negative regulator of skeletal remodeling. | 2003 | Cell | pmid:14567913 |
Zhao ZM et al. | [The preliminary study on in vitro differentiation of human umbilical cord blood cells into neural cells]. | 2003 | Zhonghua Xue Ye Xue Za Zhi | pmid:14575594 |
Boyan BD et al. | Osteoblasts generate an osteogenic microenvironment when grown on surfaces with rough microtopographies. | 2003 | Eur Cell Mater | pmid:14577052 |
Grimaud E et al. | Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis. | 2003 | Am. J. Pathol. | pmid:14578201 |
Price PA et al. | Serum levels of the fetuin-mineral complex correlate with artery calcification in the rat. | 2004 | J. Biol. Chem. | pmid:14578360 |
Coen G et al. | Serum leptin in dialysis renal osteodystrophy. | 2003 | Am. J. Kidney Dis. | pmid:14582047 |
Chagraoui H et al. | Expression of osteoprotegerin mRNA and protein in murine megakaryocytes. | 2003 | Exp. Hematol. | pmid:14585373 |
Takayanagi H | [Crosstalk between the immune and skeletal system]. | 2003 | Ryumachi | pmid:14598653 |
Naylor KE et al. | Serum osteoprotegerin as a determinant of bone metabolism in a longitudinal study of human pregnancy and lactation. | 2003 | J. Clin. Endocrinol. Metab. | pmid:14602774 |
Heim M et al. | The phytoestrogen genistein enhances osteogenesis and represses adipogenic differentiation of human primary bone marrow stromal cells. | 2004 | Endocrinology | pmid:14605006 |
Crotti TN et al. | Factors regulating osteoclast formation in human tissues adjacent to peri-implant bone loss: expression of receptor activator NFkappaB, RANK ligand and osteoprotegerin. | 2004 | Biomaterials | pmid:14607494 |
Hayashi S et al. | Distinct osteoclast precursors in the bone marrow and extramedullary organs characterized by responsiveness to Toll-like receptor ligands and TNF-alpha. | 2003 | J. Immunol. | pmid:14607912 |
Padigel UM et al. | TRANCE-RANK costimulation is required for IL-12 production and the initiation of a Th1-type response to Leishmania major infection in CD40L-deficient mice. | 2003 | J. Immunol. | pmid:14607948 |
Hortobagyi GN | Novel approaches to the management of bone metastases. | 2003 | Semin. Oncol. | pmid:14613037 |
Voskaridou E et al. | Pamidronate is an effective treatment for osteoporosis in patients with beta-thalassaemia. | 2003 | Br. J. Haematol. | pmid:14616979 |
Uemura H et al. | Circulating osteoprotegerin in women during GnRH-agonist treatment and their relationships with mineral components and biomarkers of bone turnover. | 2003 | Bone | pmid:14623063 |
Terpos E et al. | New insights into the pathophysiology and management of bone disease in multiple myeloma. | 2003 | Br. J. Haematol. | pmid:14632767 |
Zhang J et al. | Soluble receptor activator of nuclear factor kappaB Fc diminishes prostate cancer progression in bone. | 2003 | Cancer Res. | pmid:14633717 |
Chan BY et al. | Effect of anticoagulants and storage temperature on the stability of receptor activator for nuclear factor-kappa B ligand and osteoprotegerin in plasma and serum. | 2003 | Clin. Chem. | pmid:14633883 |
Jung K et al. | Serum osteoprotegerin and receptor activator of nuclear factor-kappa B ligand as indicators of disturbed osteoclastogenesis in patients with prostate cancer. | 2003 | J. Urol. | pmid:14634401 |
Su X et al. | [The effects of 17 beta-estradiol on the expression of osteoprotegerin, the ligand of osteoprotegerin and related cytokines in osteosarcoma MG63 cells]. | 2003 | Zhonghua Nei Ke Za Zhi | pmid:14636471 |
Mandelin J et al. | Imbalance of RANKL/RANK/OPG system in interface tissue in loosening of total hip replacement. | 2003 | J Bone Joint Surg Br | pmid:14653607 |
Pennisi P et al. | Low bone density and abnormal bone turnover in patients with atherosclerosis of peripheral vessels. | 2004 | Osteoporos Int | pmid:14661073 |
Miyahira Y et al. | Cutting edge: a potent adjuvant effect of ligand to receptor activator of NF-kappa B gene for inducing antigen-specific CD8+ T cell response by DNA and viral vector vaccination. | 2003 | J. Immunol. | pmid:14662831 |
Stilgren LS et al. | Osteoprotegerin levels in primary hyperparathyroidism: effect of parathyroidectomy and association with bone metabolism. | 2003 | Calcif. Tissue Int. | pmid:14667132 |
Okada T et al. | Bone marrow metastatic myeloma cells promote osteoclastogenesis through RANKL on endothelial cells. | 2003 | Clin. Exp. Metastasis | pmid:14669795 |
Gannagé-Yared MH et al. | Effects of a short-term calcium and vitamin D treatment on serum cytokines, bone markers, insulin and lipid concentrations in healthy post-menopausal women. | 2003 | J. Endocrinol. Invest. | pmid:14669830 |
Ashcroft AJ et al. | Colonic dendritic cells, intestinal inflammation, and T cell-mediated bone destruction are modulated by recombinant osteoprotegerin. | 2003 | Immunity | pmid:14670302 |
Chong B et al. | Idiopathic hyperphosphatasia and TNFRSF11B mutations: relationships between phenotype and genotype. | 2003 | J. Bone Miner. Res. | pmid:14672344 |
Nielsen KL et al. | Biglycan deficiency interferes with ovariectomy-induced bone loss. | 2003 | J. Bone Miner. Res. | pmid:14672350 |
Kumamoto H and Ooya K | Expression of parathyroid hormone-related protein (PTHrP), osteoclast differentiation factor (ODF)/receptor activator of nuclear factor-kappaB ligand (RANKL) and osteoclastogenesis inhibitory factor (OCIF)/osteoprotegerin (OPG) in ameloblastomas. | 2004 | J. Oral Pathol. Med. | pmid:14675140 |
Crotti TN et al. | Variability of RANKL and osteoprotegerin staining in synovial tissue from patients with active rheumatoid arthritis: quantification using color video image analysis. | 2003 | J. Rheumatol. | pmid:14677171 |
Buzi F et al. | Serum osteoprotegerin and receptor activator of nuclear factors kB (RANKL) concentrations in normal children and in children with pubertal precocity, Turner's syndrome and rheumatoid arthritis. | 2004 | Clin. Endocrinol. (Oxf) | pmid:14678293 |